Neonatal invasive candidiasis in low-and-middle-income countries: data from the NeoOBS study.
Cook A., Ferreras-Antolin L., Adhisivam B., Ballot D., Berkley JA., Bernaschi P., Carvalheiro CG., Chaikittisuk N., Chen Y., Chibabhai V., Chitkara S., Chiurchiu S., Chorafa E., Dien TM., Dramowski A., de Matos SF., Feng J., Jarovsky D., Kaur R., Khamjakkaew W., Laoyookhong P., Machanja E., Mussi-Pinhata MM., Namiiro F., Natraj G., Naziat H., Ngoc HTB., Ondongo-Ezhet C., Preedisripipat K., Rahman H., Riddell A., Roilides E., Russell N., Sastry AS., Tasimwa HB., Tongzhen J., Wadula J., Wang Y., Whitelaw A., Wu D., Yadav V., Yang G., Stohr W., Bielicki JA., Ellis S., Warris A., Heath PT., Sharland M.
Neonatal invasive candidiasis (NIC) has significant morbidity and mortality. Reports have shown a different profile of those neonates affected with NIC and of fluconazole resistant Candida spp. isolates in low-and-middle-income -countries (LMICs) compared to high-income-countries (HIC). We describe the epidemiology, Candida spp. distribution, treatment and outcomes of neonates with NIC from LMICs enrolled in a global, prospective, longitudinal, observational cohort study (NeoOBS) of hospitalised infants